Genprex, Inc. (GNPX) stock
GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.08−0.13 (-5.88%)
Close on Nov 13, 2026Market cap $1.70MP/E –Yield –
Genprex EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Genprex's EPS for the twelve months ending Sep 30, 2024 was -$604.22. For fiscal 2021 it was -$840.00. The highest annual figure on record is -$580.00 in fiscal 2017.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -$840.00 | – |
| FY2020 | Dec 31, 2020 | -$1020.00 | – |
| FY2019 | Dec 31, 2019 | -$1320.00 | – |
| FY2018 | Dec 31, 2018 | -$1800.00 | – |
| FY2017 | Dec 31, 2017 | -$580.00 | – |
| FY2016 | Dec 31, 2016 | -$760.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$5.30 | – |
| Q2 FY2026 | Jun 30, 2026 | -$9.40 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.64 | – |
| Q3 FY2025 | Sep 30, 2025 | -$109.39 | – |
| Q2 FY2025 | Jun 30, 2025 | -$185.30 | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.98 | – |
| Q3 FY2024 | Sep 30, 2024 | -$61.65 | – |
| Q2 FY2024 | Jun 30, 2024 | -$150.23 | – |
| Q1 FY2024 | Mar 31, 2024 | -$192.99 | – |
| Q4 FY2023 | Dec 31, 2023 | -$199.35 | – |
| Q3 FY2023 | Sep 30, 2023 | -$268.08 | – |
| Q2 FY2023 | Jun 30, 2023 | -$307.05 | – |
| Q1 FY2023 | Mar 31, 2023 | -$372.04 | – |
| Q4 FY2022 | Dec 31, 2022 | -$271.50 | – |
| Q3 FY2022 | Sep 30, 2022 | -$256.03 | – |
| Q2 FY2022 | Jun 30, 2022 | -$240.73 | – |
| Q1 FY2022 | Mar 31, 2022 | -$221.80 | – |
| Q4 FY2021 | Dec 31, 2021 | -$282.27 | – |
| Q3 FY2021 | Sep 30, 2021 | -$140.00 | – |
| Q2 FY2021 | Jun 30, 2021 | -$160.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$280.00 | – |
| Q4 FY2020 | Dec 31, 2020 | -$263.60 | – |
| Q3 FY2020 | Sep 30, 2020 | -$140.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$240.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$400.00 | – |
| Q4 FY2019 | Dec 31, 2019 | -$280.18 | – |
| Q3 FY2019 | Sep 30, 2019 | -$300.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$480.00 | – |
| Q1 FY2019 | Mar 31, 2019 | -$280.00 | – |
| Q4 FY2018 | Dec 31, 2018 | -$453.96 | – |
| Q3 FY2018 | Sep 30, 2018 | -$300.00 | – |
| Q2 FY2018 | Jun 30, 2018 | -$900.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$120.00 | – |
| Q4 FY2017 | Dec 31, 2017 | -$116.05 | – |
| Q3 FY2017 | Sep 30, 2017 | -$120.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$200.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$140.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$173.57 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?